Byterna Therapeutics (元码智药)
Shanghai circular-mRNA company pairing AI sequence design with targeted LNPs for in vivo CAR-T and personalized cancer vaccines.
1. Core Product / Service
Byterna Therapeutics (上海元码智药生物技术有限公司) was registered on 8 June 2023 in Zhangjiang, Shanghai [1]. It develops circular mRNA (cmRNA) drugs. Circular mRNA has no free ends, so it resists degradation and can keep producing protein longer than linear mRNA [4]. The company presents itself as an AI-driven circular-RNA developer, with three platforms [3][4]:
- byterna.AI — sequence design.
- cmCAR — circular-mRNA CAR constructs.
- CellectLNP — targeted lipid nanoparticles (tLNP) for delivery.
It reports in-house know-how across molecule design, circularization, chemical modification, tLNP delivery, purification and CMC [4].
Pipeline.
- BR101: a dual-target cmRNA in vivo CAR-T. CAR-T cells are generated inside the patient rather than manufactured outside the body. It is in an investigator-initiated trial (IIT, NCT07537049) [5]. The company calls it the world's first product of its kind to reach the clinic; that claim has not been independently verified.
- AI-designed personalized circular-mRNA cancer vaccine: in research, and the subject of an August 2026 collaboration with insilico-medicine [4].
Wet-lab model: not disclosed, with signs of a partner-assisted setup. No lab size or CRO partner has been disclosed. The Insilico collaboration explicitly covers "automated experimentation and intelligent manufacturing", alongside AI neoantigen prediction and sequence design [4]. That suggests some experimental and AI work may run on Insilico's automated lab infrastructure, but this is an inference. CMC know-how is described as in-house [4].
2. Target Users & Pain Points
- In vivo CAR-T: ex vivo CAR-T is expensive, slow and needs lymphodepletion. Making CAR-T cells inside the body with targeted mRNA-LNP could make cell therapy closer to an off-the-shelf drug. Circular mRNA may extend CAR expression beyond what linear mRNA gives.
- Personalized cancer vaccines: AI neoantigen selection plus a more durable mRNA format.
3. Competitive Landscape
| Player | Positioning | Vs. Byterna |
|---|---|---|
| Orna Therapeutics (US) | Circular RNA in vivo CAR-T | Closest global analog in modality |
| Capstan Therapeutics (acquired by AbbVie) | tLNP-mRNA in vivo CAR-T | Proof that big pharma will pay for in vivo CAR-T; linear mRNA |
| Chinese in vivo CAR-T startups founded after 2023 | LNP-mRNA in vivo CAR-T, also using IITs to reach humans | Same speed advantage from China's IIT route; mostly not AI-positioned |
| insilico-medicine | AI drug-discovery platform | Partner and strategic investor rather than competitor |
| xunjing-bio | AI × RNA (small molecules that drug RNA) | Shares the "AI + RNA" label but is a different modality |
4. Unique Observations
- "AI-native" is a boundary case. The core assets are cmRNA and tLNP, and the AI positioning became prominent mainly in 2026, alongside the Insilico investment and the three-way pact with quantum-computing firm Shaqiu Quantum (沙丘量子) [3]. It reads more like an AI-enabled RNA drug company than one built around an AI discovery engine. Research surveys put it in both the AI-native and non-AI new-biotech groups.
- China's IIT route explains the speed. BR101 reached humans within about three years of founding through an investigator-initiated trial, not a formal IND. This is quicker than the US path, but it does not equal regulatory clinical status. In vivo CAR-T is one of the modalities where post-2023 Chinese startups use this route most.
- The investor is also a partner. Insilico is both an investor and a collaborator, which gives Byterna AI and automation capacity without building it. It also ties the company's AI story to a single partner.
5. Financials / Funding
| Round | Date | Amount | Investors |
|---|---|---|---|
| Seed | Mar 2024 | not disclosed | Fangfu Capital (方富资本) [1] |
| Angel | Oct 2025 | "tens of millions of RMB" | Led by Sunshine Nuohe (阳光诺和); Fangfu among participants [1][5] |
| Angel+ | Dec 2025 | not disclosed | Yifeng Capital (倚锋资本), sole investor [1][5] |
| Pre-A | 22 Jul 2026 | "tens of millions of RMB" | Yifeng (follow-on); insilico-medicine (strategic) [2] |
- Cumulative: not disclosed. Each disclosed round was "tens of millions of RMB" [1][2].
- Revenue: not disclosed.
6. People & Relationships
- Co-founder & CEO: 曾贤 (Dr. Zeng Xian) [2]. The team is described as "senior industry experts plus overseas-returnee PhDs"; detailed backgrounds are not disclosed.
- Strategic partner & investor: insilico-medicine, with an R&D collaboration signed 20 August 2026 on personalized circular-mRNA cancer vaccines [4].
- Other collaborators: Shaqiu Quantum, in a three-way collaboration with Insilico announced at WAIC 2026 [3].
- Investors: Fangfu Capital, Sunshine Nuohe, Yifeng Capital, Insilico Medicine.
- Peers: xunjing-bio, anew-labs, aureka-bio.
Sources
- Pharnex Cloud (药融云) — https://www.pharnexcloud.com/trz/trz_012fffd2b1966cd16d10e9390f747222
- PEdaily (Pre-A) — https://news.pedaily.cn/202607/566685.shtml
- ifeng Finance (WAIC 2026) — https://finance.ifeng.com/c/8uwKALIPMaL
- 10jqka (Insilico collaboration) — https://stock.10jqka.com.cn/20260820/c679131853.shtml
- PharmCube (医药魔方) — https://bydrug.pharmcube.com/news/detail/bc86396ea07bb8e13af998e857a1c1d1
- CNPharm — https://www.cnpharm.com/c/2026-09-03/1106162.shtml